|
Jul 23
|
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
|
|
Jul 23
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jul 22
|
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
|
|
Jul 22
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Jul 22
|
Halozyme to Report Second Quarter 2025 Financial and Operating Results
|
|
Jul 4
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Jul 3
|
High Growth Tech Stocks In The US Market With Promising Potential
|
|
Jun 30
|
Halozyme Therapeutics Added to Russell 1000® Index
|
|
Jun 20
|
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
|
Jun 12
|
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?
|
|
Jun 5
|
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report?
|
|
Jun 4
|
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
|
|
Jun 4
|
Merck granted review of Halozyme patent claims by PTAB
|
|
Jun 4
|
Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme
|
|
May 28
|
Halozyme to Participate at Upcoming Investor Conferences
|
|
May 28
|
Implied Volatility Surging for Halozyme Therapeutics Stock Options
|
|
May 28
|
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
|
|
May 28
|
High Growth Tech Stocks To Watch In The US May 2025
|
|
May 14
|
4 Stocks With Impressive Interest Coverage Ratio to Buy Now
|
|
May 14
|
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance
|